SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $2,125,706,950 |
| Positions | 28 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| LIQUIDIA CORPORATION | LQDA | COM NEW | $647,319,259 | 8,118,892 |
| REVOLUTION MEDICINES INC | RVMD | COM | $367,404,968 | 1,961,795 |
| ABIVAX SA | ABVX | SPONSORED ADS | $207,608,952 | 1,557,924 |
| VAXCYTE INC | PCVX | COM | $127,225,411 | 2,188,636 |
| EXELIXIS INC | EXEL | COM | $84,512,985 | 1,553,262 |
| TANGO THERAPEUTICS INC | TNGX | COM | $78,153,220 | 2,500,103 |
| AVALO THERAPEUTICS INC | AVTX | COM NEW | $58,468,244 | 3,163,866 |
| XENON PHARMACEUTICALS INC | XENE | COM | $53,717,020 | 889,944 |
| ADMA BIOLOGICS INC | ADMA | COM | $47,918,309 | 5,725,007 |
| REVOLUTION MEDICINES INC | RVMD | COM | $47,157,104 | 251,800 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.